Corneal deposition after high-dose chlorpromazine hydrochloride therapy.
OBJECTIVE
To report a case of dermal and ocular changes after prolonged use of high-dose chlorpromazine hydrochloride therapy.


METHODS
This case report includes clinical history, clinical findings, and photographic images of ocular and dermal changes. RESULTS. Chlorpromazine therapy in a cumulative dosage exceeding 1,100 g resulted in dramatic skin discoloration and multiple crystalline deposits in both corneas. Anterior capsular opacities were binocularly present. These changes were sufficient to cause reduction in visual acuity.


CONCLUSIONS
Chlorpromazine deposition at high levels can cause reduction in visual acuity and significant skin discoloration.
Sydney Refractive Surgery Centre, Chatswood, NSW, Australia.
S K
SK
Webber
Y
Y
Domniz
G L
GL
Sutton
C M
CM
Rogers
M A
MA
Lawless
D014150:Antipsychotic Agents / Q000009:adverse effects*; D002746:Chlorpromazine / Q000009:adverse effects*; D003315:Cornea / Q000187:drug effects* / Q000473:pathology; D003318:Corneal Opacity / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010859:Pigmentation Disorders / Q000139:chemically induced* / Q000473:pathology; D012559:Schizophrenia / Q000188:drug therapy; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012880:Skin Pigmentation / Q000187:drug effects; D014792:Visual Acuity
D014150:Antipsychotic Agents; D002746:Chlorpromazine